Compounds > atrasentan
Page last updated: 2024-09-04

atrasentan and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

atrasentan has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schwetz, BA1

Other Studies

1 other study(ies) available for atrasentan and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
From the Food and Drug Administration.
    JAMA, 2001, Jul-04, Volume: 286, Issue:1

    Topics: Antineoplastic Agents; Atrasentan; Benzamides; Drug Approval; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orphan Drug Production; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrrolidines; United States; United States Food and Drug Administration

2001